Ch

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance

Retrieved on: 
Wednesday, August 4, 2021
Oncology, Antineoplastic drugs, Cancer treatments, Health, Chemotherapy, Occupational safety and health, Branches of biology, Tumor microenvironment

iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.

Key Points: 
  • iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.
  • iOncturas best-in-class drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology.
  • iOncturas second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study.
  • iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

Retrieved on: 
Wednesday, August 4, 2021
Reproduction, Human reproduction, Obstetrics, Fertility medicine, Cryobiology, Fertility, In vitro fertilisation, Human pregnancy, Embryo transfer, Pregnancy rate, Meta-analysis, Randomized controlled trial

The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.

Key Points: 
  • The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.
  • The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF.
  • The analyses also showed that the effect size for nolasiban was similar for ongoing pregnancy rate and live birth rate.
  • Population pharmacokinetic analyses indicated that higher exposures of nolasiban were associated with a higher probability of pregnancy.

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Tuesday, August 3, 2021

Please contact your BTIG representative to listen to the live event and schedule a virtual one-on-one meeting with Gains management team during the conference.

Key Points: 
  • Please contact your BTIG representative to listen to the live event and schedule a virtual one-on-one meeting with Gains management team during the conference.
  • BTIG expects to host more than 120 corporate management teams throughout the two-day, private event which includes thematic panels featuring key opinion leaders, fireside chats, and one-on-one meetings.
  • Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx target identification platform.
  • In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

ObsEva to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Gynaecological neoplasia, Uterine fibroid, Endometriosis, Preterm birth, Ticker symbol, Gynaecology, Clinical medicine, Medicine

Details on the presentations can be found below.

Key Points: 
  • Details on the presentations can be found below.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
  • Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.
  • ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol OBSV and on the SIX Swiss Exchange where it is trading under the ticker symbol OBSN.

Nozomi Networks Secures $100 Million Investment from Global Ecosystem of Customers and Technology Partners

Retrieved on: 
Monday, August 2, 2021
Articles, Technology, Science and technology, Ransomware, Nozomi, Internet of things, Computer security

Its the ultimate endorsement when not only a prestigious firm such as Triangle Peak Partners leads the investment, but customers and partners embrace Nozomi Networks and further validate our market leadership.

Key Points: 
  • Its the ultimate endorsement when not only a prestigious firm such as Triangle Peak Partners leads the investment, but customers and partners embrace Nozomi Networks and further validate our market leadership.
  • With ransomware and malware attacks on organizations and critical infrastructure at an all-time high, the need for Nozomi Networks solutions has never been greater.
  • This investment fuels advancements in precision OT and IoT Security as Nozomi Networks technology ensures optimal data security and network monitoring.
  • The high-quality and highly scalable AI-based technology developed by Nozomi Networks is essential for our industrial customers.

Kahuna’s New Blockchain-Based Social Media Ecosystem Set to Launch in October 2021

Retrieved on: 
Monday, August 2, 2021
Articles, Cryptocurrencies, Decentralization, Technology, Science and technology, Blockchain, Encodings

NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kahuna , a new blockchain-based, decentralized social media ecosystem for celebrities and content creators to engage with fans around the world, announces its impending launch coming October 2021.

Key Points: 
  • NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kahuna , a new blockchain-based, decentralized social media ecosystem for celebrities and content creators to engage with fans around the world, announces its impending launch coming October 2021.
  • Kahuna is the first-of-its-kind platform that combines functionalities from traditional social media platforms like Twitter, Instagram and Clubhouse, with an added dimension of a cryptocurrency economy.
  • The decentralized platform allows celebrities, athletes, musicians, artists, influencers and other creators to fully control and monetize their content.
  • The Kahuna social media ecosystem is built on the RubiX blockchain, a next-generation blockchain that is highly scalable, secure and carbon neutral through its Blockchain Green Initiative .

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
Monday, August 2, 2021
Companies, Stock market, CAC 40, STMicroelectronics, Euronext, Share repurchase, Repurchase agreement

AMSTERDAM – August 2, 2021 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares Period from July 26, 2021 to July 30, 2021
    AMSTERDAM August 2, 2021 -- STMicroelectronics N.V. (the Company or STMicroelectronics), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the Program) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) (Ticker: STM) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between July 26, 2021 to July 30, 2021 (the Period), of 277,802 ordinary shares (equal to 0.03% of its issued share capital) at the weighted average purchase price per share of EUR 33.7798 and for an overall price of EUR 9,384,083.23.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STM (ISIN: NL0000226223), in detailed form.

Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

Retrieved on: 
Monday, August 2, 2021
Lundbeck, Valby

53 LR

Key Points: 
  • 53 LR
    Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science.
  • He is an accomplished neuropharma researcher and drug developer who already knows Addex and our research programs, said Tim Dyer, CEO of Addex.
  • Dr. Kalinichev joins Addex from Ipsen where he was Director of in vivo neurology.
  • Before Lundbeck, Dr. Kalinichev held various positions at Addex, including Associate Director and Group Leader, Behavioral Neuroscience.

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021
Enzyme kinetics, Branches of biology, Organic compounds, Chemistry, Proteins, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Leading Acumatica Shipping Software ISV Announces 2021 R1 Certification

Retrieved on: 
Sunday, August 1, 2021
Business software, Accounting software, Software, Acumatica, ERP software, Computer industry, Independent software vendor

CHESHIRE, Conn., Aug. 1, 2021 /PRNewswire-PRWeb/ -- V-Technologies, LLC, a leading provider of integrated Acumatica shipping software announces 2021 R1 Certification.

Key Points: 
  • CHESHIRE, Conn., Aug. 1, 2021 /PRNewswire-PRWeb/ -- V-Technologies, LLC, a leading provider of integrated Acumatica shipping software announces 2021 R1 Certification.
  • V-Technologies' StarShip multi-carrier shipping application seamlessly integrates to Acumatica resulting in streamlined shipping and accounts receivable operations, lower costs, higher productivity and overall efficiency.
  • This Acumatica certification is awarded to the top Independent Software Vendors (ISVs), like V-Technologies, LLC, upholding the highest integration and development standard by Acumatica Solutions Labs.
  • StarShip shipping solution for Acumatica helps Acumatica customers save time and money on their Acumatica shipping and fulfillment process.